Scribe Therapeutics (SCTX) analyst forecast and price target
Analyst forecast
Based on 4 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Initiated Coverage | Buy | $60.00 | Aug 31, 2026 |
| Wells Fargo | Initiated Coverage | Overweight | $60.00 | Aug 18, 2026 |
| Leerink Partners | Initiated Coverage | Outperform | $37.00 | Aug 18, 2026 |
| Guggenheim | Initiated Coverage | Buy | $50.00 | Aug 18, 2026 |
Frequently asked questions
What is the price target for SCTX stock?
The average 12-month analyst price target for Scribe Therapeutics (SCTX) is $51.75, with a high estimate of $60.00 and a low of $37.00, across 4 analysts.
What upside do analysts see for SCTX?
The average price target of $51.75 implies 69.45% upside from the last price of $30.54.
What is the latest analyst rating on SCTX?
On Aug 31, 2026, HC Wainwright & Co. initiated coverage of Scribe Therapeutics at Buy with a price target of $60.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.